Olverembatinib
As of the edition of 20 October 2026, Olverembatinib is a small molecule: in active development; acts on ABL1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 33, 1 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ABL1 | Tyrosine-protein kinase ABL1 | P00519 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 0 | 5 | 0 |
| Phase 1 | 7 | 2 | 5 | 0 |
| Phase 2 | 15 | 2 | 9 | 1 |
| Phase 3 | 5 | 0 | 4 | 0 |
| All trials | 33 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Ascentage Pharma | Lead sponsor of trials | 2023 to now |